NCT05903339View on ClinicalTrials.gov

Clinical Trial to Evaluate the Safety and Immunogenicity of Ferritin Nanoparticles Expressing Native-like HIV-1 Envelope Trimers Followed by Boost With mRNA Lipid Nanoparticles Encoding a Native-like HIV-1 Envelope Trimer in Adults Without HIV

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

August 29, 2023

Primary Completion Date

October 30, 2025

Study Completion Date

December 21, 2025

Conditions
Hiv
Interventions
DRUG

V3G CH848 Pr-NP1 60mcg

(60 mcg)

DRUG

3M-052-AF 5mcg

(5 mcg)

DRUG

Alum 500 mcg

(500 mcg)

DRUG

V3G CH848 mRNA-Tr2 50mcg

(50 mcg)

DRUG

ACU-026-001-1 2.0mg

(2.0 mg)

DRUG

V3G CH848 Pr-NP1 100mcg

(100 mcg)

Trial Locations (6)

30303

Emory University School of Medicine, The Ponce de Leon Center CRS [Site ID: 5802], Atlanta

98104

Seattle Vaccine and Prevention CRS [Site ID: 30331], Seattle

35294-2170

Alabama CRS [Site ID: 31788], Birmingham

02115

Brigham & Women's Hospital [Site ID: 30007], Boston

02215

BIDMC VCRS [Site ID: 32077], Boston

37232-2582

Vanderbilt Vaccine (VV) CRS [Site ID: 30352], Nashville

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT05903339 - Clinical Trial to Evaluate the Safety and Immunogenicity of Ferritin Nanoparticles Expressing Native-like HIV-1 Envelope Trimers Followed by Boost With mRNA Lipid Nanoparticles Encoding a Native-like HIV-1 Envelope Trimer in Adults Without HIV | Biotech Hunter | Biotech Hunter